title: [Results in 42 non-resectable NSCLC IIA-B patients with initial concurrent Taxotere-Cisplatin chemoradiotherapy].
abstract: OBJECTIVE
  A prospective multicenter study to treat non-small cell lung cancer (NSCLC) with inductive chemoradiotherapy for improving chances of operability. If used as first-line therapy, combined treatment improves survival and it is well tolerated with a low rate of side effects.
  
  
  METHODS
  42 patients with stage IIIA-B NSCLC from which 36 could be followed.
  
  
  METHODS
  A full dose Taxotere-Cisplatin chemotherapy was given to patients with concurrent radiotherapy in 2 Gy fractions up to 60 Gy via conformal irradiation.
  
  
  RESULTS
  Local response was very high and 40.47% of patients became operable while in inoperable cases consolidation chemotherapy showed similar results as other protocols. We also found a low rate of side effects. The high rate of brain metastasis suggests that prophylactic cranial irradiation (PCI) should be considered.
authors.affiliation: Tüdôgyógyászati Klinika, DE OEC, Debrecen, 4012, Hungary. mszilasi@jaguar.unideb.hu
authors.forename: Mária
authors.initials: M
authors.lastname: Szilasi
authors.forename: Akos
authors.initials: A
authors.lastname: Horváth
authors.forename: Tamás
authors.initials: T
authors.lastname: Dolinay
authors.forename: János
authors.initials: J
authors.lastname: Szántó
authors.forename: László
authors.initials: L
authors.lastname: Brugós
authors.forename: László
authors.initials: L
authors.lastname: Lengyel
authors.forename: Sándor Sz
authors.initials: SS
authors.lastname: Kiss
authors.forename: Magdolna
authors.initials: M
authors.lastname: Kiss
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Adamecz
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D020266:Radiotherapy, Conformal; D012074:Remission Induction; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin